PT2261378E - Método de prevenção da fusão vírus:células através da inibição da função da região de iniciação de fusão em vírus de rna contendo proteínas do invólucro fusogénico de membrana de classe i - Google Patents

Método de prevenção da fusão vírus:células através da inibição da função da região de iniciação de fusão em vírus de rna contendo proteínas do invólucro fusogénico de membrana de classe i

Info

Publication number: PT2261378E
Authority: PT; Portugal
Prior art keywords: fusion; present; viruses; class; inhibiting
Prior art date: 2003-11-04

Application number

PT101820561T

Other languages

English (en)

Inventor

Robert F Garry

Russell B Wilson

Original Assignee

Univ Tulane

Autoimmune Technologies Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-04

Filing date

2004-11-03

Publication date

2013-12-09

2004-11-03 Application filed by Univ Tulane, Autoimmune Technologies Llc filed Critical Univ Tulane

2013-12-09 Publication of PT2261378E publication Critical patent/PT2261378E/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Pathology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
General Physics & Mathematics (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Food Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)

PT101820561T 2003-11-04 2004-11-03 Método de prevenção da fusão vírus:células através da inibição da função da região de iniciação de fusão em vírus de rna contendo proteínas do invólucro fusogénico de membrana de classe i PT2261378E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US51718103P	2003-11-04	2003-11-04

Publications (1)

Publication Number	Publication Date
PT2261378E true PT2261378E (pt)	2013-12-09

Family

ID=34572923

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PT101820405T PT2261376E (pt)	2003-11-04	2004-11-03	Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe i
PT04810256T PT1692265E (pt)	2003-11-04	2004-11-03	Método de prevenção de infecções virais: fusão celular por meio de inibição da função da região de partida de fusão em vírus arn com proteínas de envelope fusogénicas de membrana de classe i
PT101820561T PT2261378E (pt)	2003-11-04	2004-11-03	Método de prevenção da fusão vírus:células através da inibição da função da região de iniciação de fusão em vírus de rna contendo proteínas do invólucro fusogénico de membrana de classe i
PT101820496T PT2261377E (pt)	2003-11-04	2004-11-03	Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT101820405T PT2261376E (pt)	2003-11-04	2004-11-03	Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe i
PT04810256T PT1692265E (pt)	2003-11-04	2004-11-03	Método de prevenção de infecções virais: fusão celular por meio de inibição da função da região de partida de fusão em vírus arn com proteínas de envelope fusogénicas de membrana de classe i

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT101820496T PT2261377E (pt)	2003-11-04	2004-11-03	Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe

Country Status (13)

Country	Link
US (5)	US7491793B2 (pt)
EP (7)	EP2261380B1 (pt)
JP (1)	JP5008398B2 (pt)
AT (1)	ATE518967T1 (pt)
AU (2)	AU2004288218B2 (pt)
BR (1)	BRPI0416187A (pt)
CA (1)	CA2544848C (pt)
DK (7)	DK2261376T3 (pt)
ES (7)	ES2400456T3 (pt)
HK (6)	HK1152081A1 (pt)
PL (4)	PL2261378T3 (pt)
PT (4)	PT2261376E (pt)
WO (1)	WO2005044992A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2261376E (pt)	2003-11-04	2013-09-23	Univ Tulane	Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe i
US7682619B2 (en)	2006-04-06	2010-03-23	Cornell Research Foundation, Inc.	Canine influenza virus
US8222204B2 (en) *	2006-05-03	2012-07-17	The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC	Influenza inhibiting compositions and methods
MX2009013635A (es) *	2007-06-25	2010-05-19	Univ Tulane	Composiciones que inhiben la influenza y metodos.
WO2009005783A1 (en) *	2007-06-28	2009-01-08	Blanchette Rockefeller Neurosciences Institute	Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
US20110305749A1 (en) *	2008-08-28	2011-12-15	Mogens Ryttergaard Duch	HIV-1 Envelope Polypeptides for HIV Vaccine
EP2413962A1 (en)	2009-03-30	2012-02-08	Mount Sinai School of Medicine	Influenza virus vaccines and uses thereof
US10138276B2 (en)	2009-09-30	2018-11-27	Signablok, Inc.	Inhibition of TCR signaling with peptide variants
US20130108653A1 (en) *	2009-12-22	2013-05-02	Shervin Bahrami	Bivalent molecules for hiv entry inhibition
CN102939101A (zh)	2010-01-26	2013-02-20	科罗拉多大学董事会，法人	用于通用疫苗的流感病毒组合物和方法
EP2536425B1 (en) *	2010-02-18	2019-06-19	Icahn School of Medicine at Mount Sinai	Vaccines for use in the prophylaxis and treatment of influenza virus disease
KR20130075732A (ko)	2010-03-30	2013-07-05	마운트 시나이 스쿨 오브 메디슨	인플루엔자 바이러스 백신 및 이의 용도
WO2012045001A2 (en) *	2010-09-30	2012-04-05	Vanderbilt University	Influenza virus antibodies and immunogens and uses therefor
US9060972B2 (en) *	2010-10-30	2015-06-23	George Dacai Liu	Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
EP2758075B1 (en)	2011-09-20	2023-05-03	Icahn School of Medicine at Mount Sinai	Influenza virus vaccines and uses thereof
US9969794B2 (en)	2012-05-10	2018-05-15	Visterra, Inc.	HA binding agents
AU2013362935B2 (en)	2012-12-18	2018-10-04	Icahn School Of Medicine At Mount Sinai	Influenza virus vaccines and uses thereof
US8999925B2 (en) *	2013-02-26	2015-04-07	The Administrators Of The Tulane Educational Fund	Arenavirus inhibiting peptides and uses therefor
WO2014159960A1 (en)	2013-03-14	2014-10-02	Icahn School Of Medicine At Mount Sinai	Antibodies against influenza virus hemagglutinin and uses thereof
US9649375B2 (en) *	2013-03-14	2017-05-16	The Administrators Of The Tulane Educational Fund	Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
WO2016049380A1 (en) *	2014-09-24	2016-03-31	University Of Utah Research Foundation	Ebolavirus pre-hairpin intermediate mimics and methods of use
US10736956B2 (en)	2015-01-23	2020-08-11	Icahn School Of Medicine At Mount Sinai	Influenza virus vaccination regimens
WO2017083627A1 (en)	2015-11-13	2017-05-18	Visterra, Inc.	Compositions and methods for treating and preventing influenza
WO2017218624A1 (en)	2016-06-15	2017-12-21	Icahn School Of Medicine At Mount Sinai	Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en)	2017-04-07	2022-02-22	Icahn School Of Medicine At Mount Sinai	Anti-influenza B virus neuraminidase antibodies and uses thereof
US11690907B2 (en)	2018-06-12	2023-07-04	Kbio Holdings Limited	Vaccines formed by virus and antigen conjugation
US11696948B2 (en)	2018-06-12	2023-07-11	Kbio Holdings Limited	Vaccines formed by virus and antigen conjugation
AU2020248404A1 (en)	2019-03-25	2021-09-30	Visterra, Inc.	Compositions and methods for treating and preventing influenza
US20230014151A1 (en) *	2019-09-04	2023-01-19	The Trustees Of Columbia University In The City Of New York	Combination antiviral therapy for measles
US11479582B2 (en)	2020-10-16	2022-10-25	King Faisal University	Anti-SARS-CoV-2 fusion peptides
JP2022116482A (ja) *	2021-01-29	2022-08-10	東亞合成株式会社	ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1711888A (en)	1987-04-24	1988-12-02	Biogen, Inc.	Immunotherapeutic methods and compositions
US5747239A (en)	1990-02-16	1998-05-05	United Biomedical, Inc.	Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en)	1990-03-09	1996-10-22	Administrators Of The Tulane Educational Fund	The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en)	1993-02-01	1994-08-18	Smithkline Beecham Corporation	Vaccinal polypeptides
US5464933A (en)	1993-06-07	1995-11-07	Duke University	Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) *	1993-06-07	2002-11-12	Trimeris, Inc.	Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6037348A (en)	1996-02-09	2000-03-14	Eli Lilly And Company	Inhibition of viral replication
JPH11209281A (ja) *	1998-01-21	1999-08-03	Daikin Ind Ltd	ヘマグルチニン結合活性及びシアリダーゼ活性に対する阻害剤、及び、これを用いてウイルス又は微生物の感染を治療及び／又は予防する方法
IL127331A0 (en)	1998-11-30	1999-09-22	Yeda Res & Dev	Peptide-based vaccine for influenza
EP1167382A1 (en) *	1999-03-31	2002-01-02	Otsuka Pharmaceutical Co., Ltd.	Influenza virus hemagglutinin-binding peptides
US6750008B1 (en)	1999-07-09	2004-06-15	Trimeris, Inc.	Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
AU7089600A (en) *	1999-08-30	2001-03-26	U.S. Army Medical Research Institute Of Infectious Diseases	Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
AU3334001A (en)	2000-02-10	2001-08-20	Panacos Pharmaceuticals Inc	Assay for detection of viral fusion inhibitors
GB0022969D0 (en)	2000-09-19	2000-11-01	Chiron Spa	Influenza a virus subtype H16
JP5180422B2 (ja) *	2000-09-22	2013-04-10	ホワイトヘッドインスチチュートフォアーバイオメディカルリサーチ	Ｈｉｖ浸入のペプチドインヒビター
US7731975B2 (en) *	2001-01-31	2010-06-08	The United States Of America As Represented By The Secretary Of The Army	Chimeric filovirus glycoprotein
US7774144B2 (en) *	2001-10-26	2010-08-10	Samuel Bogoch	System and method for identifying complex patterns of amino acids
US7894999B2 (en) *	2001-03-27	2011-02-22	Samuel Bogoch	Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7420028B2 (en) *	2001-03-27	2008-09-02	Samuel Bogoch	Replikins and methods of identifying replikin-containing sequences
JP4651213B2 (ja) *	2001-03-27	2011-03-16	株式会社グライコメディクス	インフルエンザウイルス・ヘマグルチニン結合性ペプチド
US7442761B2 (en) *	2003-06-06	2008-10-28	Samuel Bogoch	Replikin peptides and uses thereof
KR100906102B1 (ko) *	2001-03-27	2009-07-07	사무엘 보고치	레플리킨 펩타이드 및 그의 이용
US7452963B2 (en) *	2001-03-27	2008-11-18	Samuel Bogoch	Replikin peptides and antibodies therefore
US7189800B2 (en) *	2001-03-27	2007-03-13	Samuel Bogoch	Replikin peptides in rapid replication of glioma cells and in influenza epidemics
WO2004002415A2 (en) *	2002-06-27	2004-01-08	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating a cytotoxic t lymphocyte immune response
WO2005016238A2 (en) *	2003-05-08	2005-02-24	Duke University	Severe acute respiratory syndrome
EP1633775A2 (en) *	2003-06-13	2006-03-15	Crucell Holland B.V.	Antigenic peptides of sars coronavirus and uses thereof
EP1648927A1 (en) *	2003-07-21	2006-04-26	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Soluble fragments of the sars-cov spike glycoprotein
PT2261376E (pt)	2003-11-04	2013-09-23	Univ Tulane	Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe i

2004
- 2004-11-03 PT PT101820405T patent/PT2261376E/pt unknown
- 2004-11-03 EP EP10182060.3A patent/EP2261380B1/en not_active Not-in-force
- 2004-11-03 PL PL10182056T patent/PL2261378T3/pl unknown
- 2004-11-03 ES ES10182018T patent/ES2400456T3/es active Active
- 2004-11-03 WO PCT/US2004/036578 patent/WO2005044992A2/en active Application Filing
- 2004-11-03 DK DK10182040.5T patent/DK2261376T3/da active
- 2004-11-03 ES ES10182049T patent/ES2435941T3/es active Active
- 2004-11-03 ES ES04810256T patent/ES2372633T3/es active Active
- 2004-11-03 PT PT04810256T patent/PT1692265E/pt unknown
- 2004-11-03 JP JP2006538450A patent/JP5008398B2/ja not_active Expired - Fee Related
- 2004-11-03 DK DK04810256.0T patent/DK1692265T3/da active
- 2004-11-03 CA CA2544848A patent/CA2544848C/en not_active Expired - Fee Related
- 2004-11-03 PL PL04810256T patent/PL1692265T3/pl unknown
- 2004-11-03 AT AT04810256T patent/ATE518967T1/de active
- 2004-11-03 DK DK10182018.1T patent/DK2261375T3/da active
- 2004-11-03 DK DK10182049.6T patent/DK2261377T3/da active
- 2004-11-03 ES ES10182040T patent/ES2425600T3/es active Active
- 2004-11-03 EP EP10182018A patent/EP2261375B1/en not_active Not-in-force
- 2004-11-03 DK DK10182056.1T patent/DK2261378T3/da active
- 2004-11-03 ES ES10182060T patent/ES2427847T3/es active Active
- 2004-11-03 EP EP04810256A patent/EP1692265B1/en not_active Not-in-force
- 2004-11-03 US US10/578,013 patent/US7491793B2/en active Active
- 2004-11-03 DK DK10182060.3T patent/DK2261380T3/da active
- 2004-11-03 PT PT101820561T patent/PT2261378E/pt unknown
- 2004-11-03 BR BRPI0416187-4A patent/BRPI0416187A/pt not_active Application Discontinuation
- 2004-11-03 PL PL10182049T patent/PL2261377T3/pl unknown
- 2004-11-03 ES ES10181974T patent/ES2392891T3/es active Active
- 2004-11-03 AU AU2004288218A patent/AU2004288218B2/en not_active Ceased
- 2004-11-03 EP EP10182040.5A patent/EP2261376B1/en not_active Not-in-force
- 2004-11-03 EP EP10182056.1A patent/EP2261378B1/en not_active Not-in-force
- 2004-11-03 PT PT101820496T patent/PT2261377E/pt unknown
- 2004-11-03 PL PL10182040T patent/PL2261376T3/pl unknown
- 2004-11-03 EP EP10181974A patent/EP2261374B1/en not_active Not-in-force
- 2004-11-03 ES ES10182056.1T patent/ES2437858T3/es active Active
- 2004-11-03 DK DK10181974.6T patent/DK2261374T3/da active
- 2004-11-03 EP EP10182049.6A patent/EP2261377B1/en not_active Not-in-force
2009
- 2009-02-17 US US12/378,558 patent/US20090264362A1/en not_active Abandoned
2010
- 2010-03-18 AU AU2010201046A patent/AU2010201046B2/en not_active Ceased
2011
- 2011-06-15 HK HK11106192.0A patent/HK1152081A1/xx not_active IP Right Cessation
- 2011-06-15 HK HK11106200.0A patent/HK1152086A1/xx not_active IP Right Cessation
- 2011-06-15 HK HK11106198.4A patent/HK1152085A1/xx not_active IP Right Cessation
- 2011-06-15 HK HK11106195.7A patent/HK1152084A1/xx not_active IP Right Cessation
- 2011-06-15 HK HK11106193.9A patent/HK1152082A1/xx not_active IP Right Cessation
- 2011-06-15 HK HK11106194.8A patent/HK1152083A1/xx not_active IP Right Cessation
2012
- 2012-05-29 US US13/482,388 patent/US8598116B2/en active Active
2013
- 2013-08-08 US US13/962,524 patent/US9056900B2/en active Active
2015
- 2015-05-13 US US14/711,364 patent/US9725487B2/en active Active

Also Published As

Publication number	Publication date
EP2261375A2 (en)	2010-12-15
DK2261378T3 (da)	2014-01-20
CA2544848A1 (en)	2005-05-19
HK1152081A1 (en)	2012-02-17
EP2261378B1 (en)	2013-10-09
EP2261374A2 (en)	2010-12-15
ATE518967T1 (de)	2011-08-15
EP1692265B1 (en)	2011-08-03
WO2005044992A2 (en)	2005-05-19
DK1692265T3 (da)	2011-11-21
WO2005044992A3 (en)	2006-12-07
PL2261376T3 (pl)	2014-04-30
HK1152084A1 (en)	2012-02-17
HK1152082A1 (en)	2012-02-17
AU2010201046A1 (en)	2010-04-08
ES2372633T3 (es)	2012-01-25
AU2004288218B2 (en)	2009-12-24
US7491793B2 (en)	2009-02-17
HK1152086A1 (en)	2012-02-17
EP2261377A2 (en)	2010-12-15
AU2004288218A1 (en)	2005-05-19
EP2261376B1 (en)	2013-07-10
EP2261374B1 (en)	2012-06-06
EP2261375B1 (en)	2013-01-23
EP2261378A2 (en)	2010-12-15
JP2007514408A (ja)	2007-06-07
PT1692265E (pt)	2011-10-11
US20090264362A1 (en)	2009-10-22
PL2261378T3 (pl)	2014-03-31
ES2427847T3 (es)	2013-11-04
US9725487B2 (en)	2017-08-08
DK2261380T3 (da)	2013-10-07
DK2261376T3 (da)	2013-10-07
JP5008398B2 (ja)	2012-08-22
EP2261376A3 (en)	2011-02-23
US20140045743A1 (en)	2014-02-13
US20120289458A1 (en)	2012-11-15
HK1152085A1 (en)	2012-02-17
EP2261376A2 (en)	2010-12-15
EP2261378A3 (en)	2011-06-15
EP2261377B1 (en)	2013-10-02
PT2261376E (pt)	2013-09-23
EP2261380B1 (en)	2013-07-17
EP2261380A3 (en)	2011-02-23
DK2261374T3 (da)	2012-09-10
EP2261375A3 (en)	2011-06-22
AU2010201046B2 (en)	2013-06-27
US20060280754A1 (en)	2006-12-14
HK1152083A1 (en)	2012-02-17
US20150239940A1 (en)	2015-08-27
EP2261374A3 (en)	2011-03-02
PL1692265T3 (pl)	2011-12-30
DK2261377T3 (da)	2014-01-06
EP2261377A3 (en)	2011-05-18
PL2261377T3 (pl)	2014-03-31
US9056900B2 (en)	2015-06-16
ES2425600T3 (es)	2013-10-16
ES2435941T3 (es)	2013-12-26
US8598116B2 (en)	2013-12-03
BRPI0416187A (pt)	2007-01-23
EP1692265A2 (en)	2006-08-23
EP1692265A4 (en)	2007-08-29
ES2392891T3 (es)	2012-12-14
ES2400456T3 (es)	2013-04-10
EP2261380A2 (en)	2010-12-15
CA2544848C (en)	2015-12-29
PT2261377E (pt)	2013-11-29
DK2261375T3 (da)	2013-04-22
ES2437858T3 (es)	2014-01-14

Publication	Publication Date	Title
HK1152084A1 (en)	2012-02-17	Method of preventing virus:cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins
NZ598000A (en)	2013-10-25	Composition for treating hbv infection
Rodamilans et al.	2018	Plant viral proteases: beyond the role of peptide cutters
Albarino et al.	2009	Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing
NO20070194L (no)	2007-04-16	Fremgangsmater for behandling av hepatitt C
CY1114356T1 (el)	2016-04-13	Αναστολεις του ιου της ηπατιτιδας c
DK1644363T3 (da)	2012-05-29	Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
WO2003033657A3 (en)	2004-05-13	Antisense antiviral agent and method for treating ssrna viral infection
WO2005007805A3 (en)	2006-05-04	ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION
WO2010055164A3 (en)	2010-07-08	Isoquinolone derivatives as inhibitors of plavivirus replication
MX2007009628A (es)	2007-11-15	Virus de acido ribonucleico en replicacion como vacunas.
J Blake et al.	2012	RNA interference for viral infections
AU2021288648A8 (en)	2023-06-29	Conjugate of double-stranded siRNA analogue
EA200601218A1 (ru)	2006-12-29	Респираторно-синцитиальный вирус с перекрёстно компенсированным геномным дефицитом
WO2002000924A3 (en)	2002-04-11	Viral phospholipase a2 enzymes, anti-viral agents and methods of use
WO2002074941A8 (de)	2002-10-24	Reportervirus mit heterologen hüllproteinen
Uhl	2023	Cellular Conflicts Between RNA Virus and Host Biology
Madsen	2015	Dependence of Two Arboviruses on the Host MicroRNA Pathway
TW200738626A (en)	2007-10-16	Methods for treating hepatitis C
TW200519210A (en)	2005-06-16	Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same